Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Celldex Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$31.27

+1.31 (+4.37%)

B 60Pipeline Score Diagnostics · Commercial
Market Cap
2.41 B
EPS
-4.27
P/E Ratio
-
Value Trade
25.78 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • Revenue

    15.00 K

  • R&D Expenses

    73.00 M

  • Operating CF

    -65.59 M

  • Total Assets

    511.25 M

  • Total Liabilities

    55.03 M

  • Equity

    456.23 M

  • D/E Ratio

    12,345

-4.18 %
Week
-11.11 %
1 Month
31.66 %
3 Month
23.27 %
6 Month
9.75 %
5 Year
-96.5 %
All Time
Cash Data
Stable

  • Cash Position

    451.46 M

  • Monthly Burn

    21.86 M

  • Runway

    19.5 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 7, 2026
Overview
Volume
599.81 K
52 Week Range
18.55 - 35.79
% held by Insiders
2.83 %
% held by Institutions
90.8 %
Enterprise Value
1.97 B
Total Shares
78.53 M
Short %
10.08 %
Float Shares
70.91 M
Company Description
HQ: 53 FRONTAGE ROAD, HAMPTON, NJ,...
Employees:198
https://www.celldex.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1 data readout example
CDX-622 Healthy volunteers
Phase 1
—
Biologics
Immunology
CDX-622 Healthy volunteers
Phase 1
—
Biologics
Immunology
CDX-622 Healthy volunteers
Phase 1
—
Biologics
Immunology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B60
Pipeline Score
$4.0B
Pipeline Value
Valuation Signal
27
Drugs Scored
1.7x
rNPV / MCap
Top 87%
Small Cap
(rank 119 of 905)
Percentile Rank
Celldex Therapeutics, Inc. holds a solid B-grade pipeline (60/100), with $6.9B risk-adjusted pipeline value, led by Barzolvolimab in Atopic Dermatitis (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
barzolvolimab
Monoclonal antibody		Chronic Spontaneous UrticariaPhase 3NCT0644502368% $1.1B ACTIVE NOT_RECRUITING 3,517 VERY_FAST B (69) Apr 1, 2027MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
barzolvolimab
chronic spontaneous urticaria (CSU)
Phase 2
2025-06-16
barzolvolimab
chronic spontaneous urticaria (CSU)
Phase 2
2025-06-16
barzolvolimab
chronic spontaneous urticaria (CSU)
Phase 2
2025-06-16
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CLDX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CLDX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CLDX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CLDX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
CLDX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
CLDX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Celldex Therapeutics, Inc. (CLDX) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How CLDX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Urticaria #2 of 11 PHASE 3 barzolvolimab
NVS PFE EVMN
$2.5B 0.88 CONTENDER
Skin Disorders #6 of 15 PHASE 2 barzolvolimab
INCY SNY LLY
—0.85 FOLLOWER
Atopic Dermatitis #15 of 25 PHASE 2 Barzolvolimab
LLY ABBV PFE
$20.76B 0.91 FOLLOWER
Asthma #15 of 16 PHASE 1 CDX-622
NVS TEVA GSK
$30.84B 0.85 FOLLOWER